Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) unit, Fosun Wanbang (Jiangsu) Pharmaceutical Group, has secured approval from China's National Medical Products Administration to register its foritinib succinate capsules, according to a Hong Kong stock exchange filing on Thursday.
The drug is primarily used to treat non-small cell lung cancer patients that are anaplastic lymphoma kinase-positive and those with non-small cell lung cancer (ROS1+), the pharmaceutical company said.
Shares of Fosun Pharma rose over 2% in Hong Kong and nearly 1% in Shanghai in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.